fda ruling on tirzepatide is NO longer in SHORTAGE. What You Need to Know FDA approves tirzepatide, Eli Lilly's

Light-headedness, dizziness, or feeling faint may occur particularly during the initial weeks of treatment or following dose increases

Azad KM, Sutradhar SR, Khan NA, et al

Therapeutic options in this particular patient group are therefore limited

Given the effects of Semaglutide on blood sugar levels, doctors have been prescribing it for some patients with type 2 diabetes for more than 15 years

Weight loss occurs but plateaus quickly compared to the steady progression typically seen with injectable tirzepatide timelines

Elijovich F, Weinberger MH, Anderson CA, Appel LJ, Bursztyn M, Cook NR, Dart RA, Newton-Cheh CH, Sacks FM, Laffer CL, et al